STAT+: Closely watched experimental Parkinson’s drug fails key clinical trial

Biogen and Denali Therapeutics announced that their experimental Parkinson's disease drug failed to meet primary endpoints in a Phase 2b clinical trial involving 648 patients. The drug targeted LRRK2 protein, which researchers had hoped could benefit all Parkinson's patients, but the results represent a significant setback to this therapeutic approach.